Validation experiment designed to validate causal mechanisms targeting Cx43 in UAC rats treated with Gap26 inhibitor. Primary outcome: Mitigation of degenerative changes and suppressed Wnt signaling
A therapeutic intervention study using Gap26 Connexin 43 inhibitor in the unilateral anterior crossbite rat model to evaluate its potential as a treatment for TMJOA. This experiment tested whether pharmacological inhibition of Cx43 could prevent or ameliorate the degenerative changes, Wnt/β-catenin pathway activation, and cartilage degradation observed in the UAC model, providing evidence for Cx43 as a potential therapeutic target.
Administration of Gap26 inhibitor to UAC rats followed by assessment of TMJ degeneration, Cx43 activity, and Wnt/β-catenin signaling compared to untreated controls
Gap26 treatment would reduce TMJ degeneration and suppress pathological signaling pathways
Demonstration of reduced cartilage degeneration, decreased Cx43 activity, and suppressed Wnt/β-catenin signaling compared to untreated UAC controls
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.